Table 3.
Adverse events and new bone fractures during treatment.
| Denosumab (N = 69) | Romosozumab (N = 69) | |
|---|---|---|
| All adverse events | 6 (8.7) | 25 (36.2) |
| Serious adverse events | ||
| Breast cancer | 0 | 1 (1.4) |
| Injection site reaction* | ||
| Pain | 0 | 10 (14.5) |
| Swelling | 0 | 4 (5.8) |
| Redness | 0 | 1 (1.4) |
| Itching | 0 | 2 (2.9) |
| Other events of interest | ||
| Anacatesthesia | 0 | 1 (1.4) |
| Blindness | 1 (1.4) | 0 |
| Numbness in limbs | 1 (1.4) | 0 |
| Diarrhea | 1 (1.4) | 0 |
| Blood pressure elevation | 0 | 1 (1.4) |
| Fatigue | 0 | 1 (1.4) |
| New fractures during the therapy | ||
| Thoracic or lumbar spine | 2 (2.9) | 2 (2.9) |
| Proximal tibial fracture | 0 | 1 (1.4) |
| Rib fracture | 1 (1.4) | 0 |
| Distal fibular fracture | 0 | 1 (1.4) |
Data are expressed as the number of subjects (%).
*Injection site reactions included adverse events on the skin at the injection site lasting 2 days or longer.